05 August 2020 - Authored by:Jeanne Fabre & Eveline Van Keymeulen
At the end of the Conventional Policy Steering Committee held on 23 July 2020, the French Pharmaceutical Companies Association (Leem) and the French Economic Committee for Health Products (CEPS) agreed to an extension of their Framework Agreement, which is the reference framework for fixing and regulating medicines pricing in France.
The agreement, which would have otherwise expired on 31 July 2020, is now valid until 31 December 2020.
A prior version of this post was originally published by the same authors in Practical Law – Life Sciences, August 2020 Issue (Thomson Reuters).
Print Friendly
Read comments below or add a comment
Comments published on the Life Sciences Hub do not necessarily reflect the views of Allen & Overy or its clients.